Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

Key Takeaways MDGL posted a Q4 loss of $2.57 per share as operating expenses surged sharply.Rezdiffra sales drove $321.1M in Q4 revenues, beating estimates on strong demand.Madrigal ended 2025 with $958.4M in sales as phase III studies advance toward full approval.Madrigal Pharmaceuticals (MDGL) reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus Estimate of earnings of 4 cents. The large difference is mainly due to a significant rise in operating expenses. In the same ...